Tissue-specific Regulation of the Ecto-5′-nucleotidase Promoter: ROLE OF THE cAMP RESPONSE ELEMENT SITE IN MEDIATING REPRESSION BY THE UPSTREAM REGULATORY REGION by Spychala, Jozef et al.
Tissue-specific Regulation of the Ecto-5*-nucleotidase Promoter
ROLE OF THE cAMP RESPONSE ELEMENT SITE IN MEDIATING REPRESSION BY THE UPSTREAM
REGULATORY REGION*
(Received for publication, January 11, 1999, and in revised form, May 13, 1999)
Jozef Spychala‡, Albert G. Zimmermann, and Beverly S. Mitchell
From the Departments of Pharmacology and Internal Medicine, Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, North Carolina 27599-6573
We have isolated the 5* region of the ecto-5*-nucleotid-
ase (low Km 5*-NT) gene and established that a 969-base
pair (bp) fragment confers cell-specific expression of a
CAT reporter gene that correlates with the expression of
endogenous ecto-5*-NT mRNA and enzymatic activity. A
768-bp upstream negative regulatory region has been
identified that conferred lymphocyte-specific negative
regulation in a heterologous system with a 244-bp de-
oxycytidine kinase core promoter. DNase I footprinting
identified several protected areas including Sp1, Sp1/
AP-2, and cAMP response element (CRE) binding sites
within the 201-bp core promoter region and Sp1, NRE-
2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the up-
stream regulatory region. Whereas the CRE site was
essential in mediating the negative activity of the up-
stream regulatory region in Jurkat but not in HeLa
cells, mutation of the Sp1/AP-2 site decreased promoter
activity in both cell lines. Electrophoretic mobility shift
assay analysis of proteins binding to the CRE site iden-
tified both ATF-1 and ATF-2 in Jurkat cells. Finally,
phorbol 12-myristate 13-acetate increased the activity of
both the core and the 969-bp promoter fragments, and
this increase was abrogated by mutations at the CRE
site. In summary, we have identified a tissue-specific
regulatory region 5* of the ecto-5*-NT core promoter that
requires the presence of a functional CRE site within
the basal promoter for its suppressive activity.
Ecto-59-nucleotidase (low Km 59-NT,
1 ecto-59-NT, EC 3.1.3.5)
is an extracellular enzyme that is anchored to the cell mem-
brane through a glycosyl phosphatidylinositol linkage. The en-
zyme dephosphorylates purine and pyrimidine nucleoside
monophosphates to the corresponding nucleosides and gener-
ates adenosine from extracellular AMP. Adenosine may then
interact with a family of cognate receptors to produce a wide
range of physiological effects that include the regulation of
cardiovascular and cerebral blood flow (1), cytoprotection in
myocardial and cerebrovascular ischemia (2), and inhibition of
many aspects of immune function (3–6). Adenosine, which may
accumulate to high concentrations in solid tumors, has also
been postulated to be an important factor in stimulating an-
giogenesis (7), cancer growth through the increased expression
of A1 adenosine receptors (8), and in inhibiting the immune
response toward the malignant tissue (9). Therefore, investi-
gating the regulation of adenosine-metabolizing enzymes may
have important impact on the understanding of tumor biology.
The activity of ecto-59-nucleotidase, although variable, is
frequently decreased as a result of neoplastic transformation of
cells of hematopoietic origin (10). In contrast, elevated activity
of ecto-59-NT has been found in breast carcinoma (11), gastric
cancer (12), pancreatic cancer (13), chronic myelogenous leuke-
mia (10, 14), cutaneous T-cell lymphoma (15), and Walker 256
carcinoma (16). Human renal carcinoma cell lines induced to
differentiate by butyric acid have demonstrated both an in-
crease (Cur cell line) and a decrease (Caki cell line) in ecto-
59-NT activity (17), demonstrating a complex, and perhaps
context-dependent, pattern of ecto-59-NT expression in differ-
entiation and malignant transformation.
The expression of ecto-59-NT in thymocytes, lymphocytes,
granulocytes, and undifferentiated myeloid cells is very low.
However, differentiation of myeloid precursors along the mono-
cytic lineage into macrophages results in a sharp increase in
activity (18–20). The enzyme activity is lower than normal or
undetectable in lymphocytes from patients with chronic lym-
phocytic leukemia and infectious mononucleosis (21) and in
CD81 lymphocytes from AIDS patients (22). Given the strong
immunosuppressive activity of adenosine, it seems likely that
the variability in expression of this enzymatic activity among
lymphoid cell populations has functional significance. In order
to characterize the regulatory elements that contribute to the
transcriptional regulation and tissue-specific expression of
ecto-59-NT, we have characterized the core promoter and up-
stream regulatory regions of the human gene.
EXPERIMENTAL PROCEDURES
Materials—Fetal calf serum was obtained from HiClone and Sigma.
TRI Reagent, a high efficiency hybridization system, and Northern/
Southern transfer solution were obtained from Molecular Research
Center Inc. (Cincinnati, OH). Restriction enzymes, Klenow fragment of
DNA polymerase, Taq polymerase, and polynucleotide kinase were
from Promega (Madison, WI). Reverse transcriptase was from Life
Technologies, Inc. D-threo[dichloroacetyl-1-14C]chloramphenicol (56
mCi/mmol) was from Amersham Pharmacia Biotech.
Cells—The T-lymphoblast cell line K-T1 (23) was obtained from Dr.
D. Sorscher (University of North Carolina). The K562 erythroleukemia
cell line (ATCC CCL-243), Jurkat T-cell line (T-ALL origin), U937 cell
line, PC-12 pheochromocytoma, HeLa S3 cervical carcinoma, and WI-38
fibroblasts were obtained from the ATCC (Manassas, VA). Jurkat,
K-T1, K562, and U937 cells were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum. WI-38, PC-12, and HeLa S3
cell lines were maintained in Eagle’s minimal essential medium sup-
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plemented with 10% fetal calf serum, nonessential amino acids, sodium
pyruvate, penicillin, and streptomycin.
Northern Blot Analysis—Total cellular RNA (20 mg) purified by the
acid guanidinium thiocyanate/phenol/chloroform method (24) was elec-
trophoresed in 1% agarose with 50 mM MOPS, pH 7.0, and 1 M formal-
dehyde buffer. The RNA was transferred to Nytran nylon membranes
overnight, fixed in a vacuum oven at 80 °C for 30 min, and probed with
a randomly primed 1660-bp AvaI/HindIII cDNA fragment extending
from bp 8 to 1668 of the ecto-59-NT coding region (25). Hybridization
was performed in high efficiency hybridization solution with 50% form-
amide, with a nylon membrane sandwiched between two Whatman
3MM papers, in a rotating incubator at 42 °C for 24 h. Blots were
washed twice in 13 SSC, 0.2% SDS at room temperature and once at
60 °C and exposed overnight at 280 °C.
Plasmid/Promoter Constructs—The chloramphenicol acetyltrans-
ferase (CAT) vector pCAT-Basic (Promega, Madison, WI) was used in
reporter gene assays to examine ecto-59-NT promoter activity. The
corresponding promoter fragments were generated by restriction di-
gests or by PCR as described previously (26). PCR was performed using
Pfu polymerase (Stratagene, La Jolla, CA) followed by five cycles with
Taq polymerase (Roche Molecular Biochemicals). The PCR products
were cloned into the pCR 2.1 vector (Invitrogen, Carlsbad, CA) and
sequenced. The heterologous ecto-59-NT/deoxycytidine kinase (dCK)
promoter construct was produced by replacing a PstI/NdeI fragment
encompassing the 59-NT proximal promoter fragment and part of the
CAT gene from pCAT-Basic with the corresponding dCK-244 PstI/NdeI
fragment containing the 244-bp dCK promoter (27). Plasmid DNA used
for transfections was purified using Quiagen Maxi columns, and isopro-
pyl alcohol-precipitated plasmid DNA preparations were further depro-
teinated by the sequential treatment with equal volumes of phenol/
chloroform/isoamyl alcohol (50:49:1) and twice with chloroform. Final
plasmid DNA preparations were precipitated in the presence of 0.1 M
sodium acetate with 70% ethanol, washed with 75% ethanol, and sus-
pended in H2O at 2 mg/ml. The quality of DNA was tested on agarose
gel electrophoresis with and without treatment by HindIII and XbaI.
Cell Transfections—Cells were transfected by electroporation using a
Bio-Rad Gene-Pulser. Approximately 6.0 3 106 Jurkat, K-T1, K562, or
U937 cells; 3.0 3 106 HeLa cells; and 1.0 3 106 fibroblasts were trans-
fected at room temperature in RPMI 1640 medium with equimolar
amounts of the promoter constructs corresponding to 20 mg of control
pCAT-Basic plasmid. Herring sperm DNA was added to a total quantity
of 50 mg of DNA/electroporation. Electroporation efficiency was deter-
mined by transfecting separate aliquots of cells with 20 mg of b-galac-
tosidase plasmids driven by b-actin promoter and 30 mg of herring
sperm DNA. When the effect of PMA was tested on ecto-59-NT promoter
activity, co-transfection of b-galactosidase and CAT constructs was
performed to account for variable cell growth rates in the presence of
PMA. Electroporations were performed at 300 V and 960 microfarads
(330 V and 960 microfarads for HeLa cells), and cells were subsequently
suspended in 12 ml of RPMI 1640 medium containing 20% horse serum.
After 44–48 h, cells were harvested, washed with cold PBS, and freeze-
thawed three times with 80 ml of 0.25 M Tris, pH 8.0, containing 0.1 mM
phenylmethylsulfonyl fluoride and 10 mg/ml pepstatin and leupeptin.
CAT activity assays were performed on supernatants following treat-
ment of extracts at 62 °C for 10 min.
CAT and b-Galactosidase Assays—Chloramphenicol acetyltrans-
ferase activity was measured at 37 °C in a reaction medium containing
1 mM dibutyryl CoA (25 mg/assay), 10 mM D-threo[dichloroacetyl-1-
14C]chloramphenicol (56 mCi/mmol, 0.25 mCi/assay) in 0.25 M Tris, pH
8.0, buffer. The incubation was initiated by the addition of 2–50 ml of
cell extract in a total volume of 125 ml and terminated after 1–6 h with
the addition of 300 ml of xylenes. Following three extractions, reaction
products in the organic phase were counted in a scintillation counter.
Reaction velocity was expressed as cpm converted/h/mg of protein.
Reaction time and extract amount were adjusted so that no more than
30% of substrate was utilized. The final results are expressed as the
-fold increase or decrease over values obtained with the pCAT Basic
vector alone. To normalize for transfection efficiency, the CAT activity
was divided by the b-galactosidase activity of simultaneous transfec-
tions. b-Galactosidase activity was assayed spectrophotometrically at
564 nm in 25 mM phosphate buffer, pH 7.5, 5 mM MgCl2, and 3 mg/ml
chlorophenol red-b-D-galactopyranoside at 37 °C. The reaction was ini-
tiated by the addition of 5–25 ml of cell extract and analyzed for 1 min.
The linear portion of the curve was used to compute 0 order reaction
rate and expressed as mmol of substrate used/min/mg of protein. The
b-galactosidase activity varied by less than 20% in duplicate cell sam-
ples. Protein concentration was assayed by the Bradford method (28).
Preparation of Nuclear Extracts—Extracts were made from logarith-
mically growing Jurkat T cells according to the method of Dignam et al.
(29) with modifications as described by Blake et al. (30). Cells were
homogenized in buffer A (10 mM HEPES, pH 7.9, 0.75 mM spermidine,
0.15 mM spermine, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM DTT,
1 mM phenylmethylsulfonyl fluoride, 100 nM ocadaic acid), and the
nuclei were recovered by centrifugation at 30,000 3 g for 30 s. Nuclear
factors were extracted in buffer C (20 mM HEPES, pH 7.9, 0.2 mM
EDTA, 0.2 mM EGTA, 2 mM DTT, 20% glycerol, 0.15 mM spermine, 0.75
mM spermidine, 1 mM phenylmethylsulfonyl fluoride, 0.4 M NaCl, 100
nM ocadaic acid), followed by centrifugation at 30,000 3 g for 45 min.
The supernatant was dialyzed in buffer D (20 mM HEPES, pH 7.9, 20%
glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM EGTA, 2 mM DTT, 1 mM
phenylmethylsulfonyl fluoride, 12.5 mM MgCl2), aliquoted, and stored
at 270 °C (31).
DNase I Footprinting—Two DNA probes encompassing the 378-bp
fragment (from 248 to 2426 from the ATG site, cluster I and II, Fig. 4)
and 406-bp fragment (from 2425 to 2832, cluster III) were generated
by PCR with Pfu DNA polymerase. Resulting fragments were incubated
with the Taq polymerase, subcloned into the pCR 2.1 vector, and di-
gested with the appropriate restriction enzymes to create a 59-overhang
on the noncoding strand at the 39-end. The 39- ends of the coding strands
were filled in with radiolabeled dCTP using DNA polymerase large
Klenow fragment. The resulting probes were digested at the opposite
end to ensure one-strand labeling, gel-purified on a 6% nondenaturing
polyacrylamide gel, and eluted by the “crush and soak” method (29).
DNase I footprinting was performed according to Blake et al.(30). Ten
ng of 32P-labeled DNA were incubated with 120 and 240 mg of Jurkat
and HeLa cell nuclear extracts in the presence of 15 mg of poly(dI-dC),
6.1% glycerol, 0.07 mM EDTA, 0.07 mM EGTA, 7.2 mM HEPES, pH 7.9,
39 mM KCl, 7.5 mM MgCl2, and 0.7 mM DTT. The binding reactions were
performed at room temperature for 30 min, after which CaCl2 (2 mM
final concentration) was added, and the probe was digested with DNase
I (Worthington) at room temperature for 3 min. Digestions were termi-
nated by the addition of 2 volumes of 100 mM Tris, pH 8.0, 20 mM EDTA,
0.1% SDS, 100 mg/ml proteinase K, and 100 mg/ml glycogen. After an
incubation at 37 °C for 20 min, the samples were extracted with phenol/
chloroform, precipitated with ethanol, resuspended in formamide load-
ing dye, and analyzed on an 8 M urea, 6% polyacrylamide sequencing
gel.
Electrophoretic Mobility Shift Assay (EMSA)—Wild-type and mutant
double-stranded oligonucleotides were generated by annealing comple-
mentary single-stranded oligonucleotides yielding 59-overhangs; 100 ng
was labeled by fill-in using Klenow fragment of DNA polymerase.
Labeled probes were purified on 1 ml of Sephadex-G50 (Sigma) col-
umns. The flow-through was precipitated with 1⁄10 volume of 3 M sodium
acetate and 2.5 volumes of ethanol, washed with 75% ethanol, and
resuspended at 20,000 cpm/ml. For competition experiments, unlabeled
wild-type and mutant oligonucleotides were prepared by using unla-
beled deoxynucleotides for fill-in and precipitated as described above.
One ml of probe (approximately 0.1 ng of DNA) was incubated with 8 mg
of nuclear extract in the presence of 20 mM HEPES, pH 7.5, 0.5 mM
DTT, 1 mM EDTA, 2 mM MgCl2, 50 mM KCl, 12% glycerol, and 2 mg of
poly(dI-dC) (Sigma). Reactions were preincubated on ice for 10 min in
the presence of competitor or for 30–60 min in the presence of antibod-
ies. Probe was added to the mixture, and the reaction was incubated at
room temperature for 20 min. The protein-DNA complexes were re-
TABLE I
Sequences of mutated CRE, Sp1, and Sp1/AP-2 sites and of oligonucleotides used in EMSA
Site Wild type Mutateda For EMSA (wild type)




a Mutated nucleotides are underlined.
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solved on native 4% polyacrylamide (30:1 acrylamide/bisacrylamide),
0.53 Tris-borate-EDTA minigels at 100 V, dried, and autoradio-
graphed. EMSA supershift experiments were performed with 1 mg of
each of the following antibodies: ATF-1 antibody (sc-241X), ATF-2 (sc-
242X), CREB-1 (sc-186X), CREB-2 (sc-200), CREM-1 (sc-440X), c-Jun
(sc-1694X), and c-Fos (sc-413) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA).
59-Nucleotidase Assay—Ecto-59-NT activity in cell extracts was
measured in 50 mM Tris, pH 7.5, buffer containing 20 mM MgCl2, 5 mM
b-glycerophosphate, 0.1 mM erythro-9(2-hydroxy-3-nonyl)adenine
(EHNA; inhibitor of adenosine deaminase), and 20 mM [8-14C]AMP.
Reaction products were separated on plastic-supported cellulose (Ko-
dachrome; Eastman Kodak Co.) in ammonia/butanol/methanol/H20 (1:
20:20:60), and corresponding spots were visualized under UV light,
excised, and counted in a scintillation counter.
RESULTS
Cell-specific Expression of Ecto-59-nucleotidase mRNA—To
determine the level of ecto-59-NT mRNA in human cell lines,
Northern blot analysis was performed (Fig. 1). A high level of
expression of a single 4.1-kilobase mRNA was observed in
cultured human fibroblasts (WI38), whereas HeLa cells ex-
pressed an intermediate level, and PC-12, U937, Jurkat, K562,
and K-T1 cells had low or undetectable levels. The correspond-
ing ecto-59-NT enzyme activities in cell homogenates were
319.3 6 20.6, 29.9 6 6.1, 6.3 6 2.4, 2.40 6 0.62, 0.37 6 0.17,
0.12 6 0.14, and 0.40 6 0.22 nmol/min/mg of protein, respec-
tively (6S.D., 3–5 independent measurements). There was a
863-fold difference in 59-nucleotidase activity between fibro-
blasts and the Jurkat T-cell line, and relative enzyme activities
in different cell lines corresponded with differences in the lev-
els of mRNA expression.
Cell-specific Activity of the Ecto-59-nucleotidase Promot-
er—In order to determine the relative levels of ecto-59-NT pro-
moter activity, we transiently transfected several cell lines
with the pCAT-Basic reporter construct containing 969, 371, or
201 bp of the promoter. As shown in Fig. 2, the full-length
969-bp promoter fragment yielded CAT activity that was con-
sistently lower than the marginal activity of the pCAT-Basic
vector in Jurkat, K-T1, and K562 cell lines, whereas relative
CAT activity in U937, HeLa, and WI-38 cells was increased by
10–25-fold. Two further deletions of 59-sequences, producing
371- and 201-bp promoter fragments, caused moderate in-
creases in promoter activity in Jurkat T-cells and K562 cells, no
significant changes in U937 and HeLa cells, and a significant
FIG. 1. Northern blot analysis of ecto-5*-nucleotidase mRNA
levels in human cell lines. Twenty mg of total RNA were loaded in
each lane. Upper panel, 4.1-kb ecto-59-NT mRNA; lower panel, 18 and
28 S rRNA stained with ethidium bromide.
FIG. 2. Cell specificity of ecto-5*-nucleotidase promoter frag-
ment activity in different human cell lines. Promoter constructs
were generated as described under “Experimental Procedures.” Values
represent the mean 6 S.D. of 3–5 independent determinations done in
duplicate. *, mean values from two independent experiments. **, in
PC-12 cells, only the 201- and 969-bp constructs were tested.
FIG. 3. Sequence of the ecto-5*-nu-
cleotidase promoter with putative
transcription factor binding sites.
Four clusters of binding sites were iden-
tified within the proximal 969-bp frag-
ment. Bases are numbered in relation to
the ATG translation start site in the first
exon. Consensus transcription factor
binding sites are in boldface type and un-
derlined. Clusters I/II and III were ana-
lyzed with a DNase I protection assay,
and protected areas are double under-
lined. Hypersensitive sites are indicated
with arrows.
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decrease in promoter activity in WI38 fibroblasts (Fig. 2).
These data suggest that the distal 768-bp fragment contains
tissue-specific regulatory elements that function to repress the
core promoter activity in lymphoid (Jurkat and K-T1) and
erythroid (K562) cell lines while enhancing the activity in
WI-38 fibroblast. In general, the promoter activity in transient
transfection assays correlated well with the levels of mRNA
and ecto-59-NT enzymatic activity in a majority of cell lines.
In Vitro DNase I Footprinting—To identify regulatory ele-
ments that interact with cognate transcription factors, we per-
formed in vitro DNase I footprinting analysis using Jurkat
T-cell and HeLa nuclear extracts. Four clusters of putative
transcription factor binding sites were identified within the
proximal 770 bp of the ecto-59-NT promoter (Fig. 3). We have
generated two DNA probes that encompass cluster I/II and
cluster III and used them in DNase I footprinting analysis with
Jurkat T-cell and HeLa nuclear extracts. Results presented in
Fig. 4 demonstrate that within the core promoter region (clus-
ter I/II) both Jurkat (A) and HeLa (B) nuclear extracts produce
similar protected areas that coincide with Sp1, Sp1/AP-2, and
CRE transcription factor binding sites. However, within cluster
III, a strong protected area coincident with a TCF-1/LEF-1
consensus binding site (32–34) is present with extract from
Jurkat cells but is absent with HeLa nuclear extracts. Further
upstream, an extensive 22-bp protected area that coincides
with adjacent NF-AT and Sp1 binding sites in Jurkat corre-
sponds to a more restricted 16-bp protected area representing a
single Sp1 site in HeLa extracts. An additional protected area
further upstream coincides with a NRE-2a/2b transcription
factor binding site (35) and is also more pronounced with the
Jurkat T-cell nuclear extract. A protected area that does not
correspond to a known consensus transcription factor binding
site is present at bp 2579 to 2599 only with Jurkat T-cell
nuclear extract.
Cell-specific Activity of the Upstream Regulatory Region in a
Heterologous System—To determine whether the silencing/en-
hancing activity of the upstream regulatory region is specific
for the ecto-59-NT promoter or could be reproduced in a heter-
ologous system, we generated a chimeric promoter construct
containing the distal 768 bp of the regulatory region ligated to
the 244-bp core promoter of the human dCK gene (27) (Fig. 5A).
As shown in Fig. 5B, the 59-NT upstream promoter fragment
decreased CAT expression mediated by the dCK promoter
alone in Jurkat and K-T1 cells by 78%, whereas it had a lesser
suppressive effect on dCK promoter-mediated CAT expression
in HeLa cells (decrease by 40%) and no effect in WI38 fibro-
blasts. The lack of enhancer activity in fibroblasts, as seen with
the native ecto-59-NT core promoter (Fig. 2), suggests that
either the dCK core promoter activity was already maximal or
that the function of the enhancer is promoter-specific.
Mutational Analysis of the Ecto-59-NT Core Promoter—To
further investigate the importance of the Sp1, AP-2, and CRE
transcription factor binding sites within the core promoter
region, we mutated these sites as illustrated in Table I and
tested the respective mutants individually in transient trans-
fection assays. Data presented in Fig. 6 show that none of the
mutations in the context of the 201-bp core promoter region
had any significant effect in either Jurkat or HeLa cells. How-
ever, within the context of the 969-bp promoter fragment, mu-
tation of the CRE site at bp 184–185 produced a dramatic
increase of the promoter activity to the level found with the
wild-type 201-bp core promoter region alone in Jurkat cells,
while resulting in a 50% decrease in HeLa cells (Fig. 6). Mu-
tations at the Sp1 and especially at the Sp1/AP-2 site brought
about significant decreases in promoter activity in both Jurkat
and HeLa cells. In Jurkat T-cells, the wild-type 969-bp pro-
moter activity was strongly suppressed to a level of 40 6 10%
of pCAT-Basic vector alone (Fig. 2) and decreased further to
15 6 10% (6 S.D. from four experiments) of pCAT-Basic with
mutation at the Sp1/AP-2 site. These data suggest that tran-
FIG. 4. DNase I protection assay of the ecto-5*-nucleotidase
promoter fragments corresponding to clusters I/II and III. Nu-
clear extracts from Jurkat T-cells (A) and from HeLa cells (B) were
prepared and processed as described under “Experimental Procedures.”
DNA markers are shown on the right. AP-2 footprint represents a
combined Sp1/AP-2 transcription factor binding site.
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scription factors binding to the CRE and Sp1/AP-2 sites may
influence the activity of the upstream regulatory region.
Identification of Transcription Factors Binding to the CRE
Site—We next employed EMSAs with a probe encompassing
the CRE site to identify cognate transcription factors (Table I).
We used a panel of antibodies recognizing members of the
CREB and ATF family of proteins and c-Fos and c-Jun tran-
scription factors known to dimerize with members of the CREB
family. Results shown in Fig. 7 demonstrate that antibodies
recognizing CREB-1, CREB-2, CREM-1, c-Fos, and c-Jun were
not able to supershift the DNA-protein complexes, whereas
antibodies against ATF-1 and ATF-2 caused distinctly de-
creased intensities of the corresponding lower band coincident
with the appearance of a more pronounced (ATF-1) or a new
(ATF-2) upper band (Fig. 7, A and D). The intensity of the
supershifted band with ATF-2-specific antibody was similar
with nuclear extracts prepared from control and PMA-treated
cells; however, there was a somewhat less pronounced decrease
in ATF-2-specific lower complex intensity with PMA-treated
nuclear extracts (Fig. 7D). Similar results were obtained with
polyclonal antibody against ATF-2 (data not shown). Mutated
CRE probe did not produce specific band shifts (Fig. 7C). These
results suggest that ATF-1 and ATF-2 or closely related pro-
teins specifically interact with the CRE site in the ecto-59-NT
core promoter in Jurkat T-cells. In contrast, in HeLa nuclear
extract, despite the presence of strong gel shifts, none of the
specific antibodies described above resulted in a supershifted
complexes (data not shown).
Effect of PMA on Ecto-59-NT Promoter Activity in Jurkat
T-cells—We have previously shown that induction of promyelo-
cytic HL60 cells to differentiate with PMA coincided with a
dramatic increase in ecto-59-NT mRNA level (20). Since the
CRE site has been identified as a PMA-responsive element
through the modulation of the ATF-2 transcription factor (36,
37), we tested the possibility that in Jurkat T-cells PMA might
increase ecto-59-NT promoter activity through activation of a
transcription factor binding to this site. Results presented in
Fig. 8 show that activity of the 201-bp promoter fragment was
induced up to 3-fold by a 20-h treatment with 20 nM PMA,
whereas the same promoter fragment with a mutated CRE site
was not affected. Furthermore, the 969-bp promoter fragment
was activated approximately 17-fold by PMA. Mutation of the
CRE site in the 969-bp fragment increased the promoter activ-
ity as described previously in Fig. 6, and PMA did not further
increase this activity.
Mutational Analysis of the TCF-1/LEF-1 Transcription Fac-
tor Binding Site—A limited number of promoters or enhancers
have been shown to contain consensus sites for the develop-
mentally important transcription factors TCF-1 and LEF-1.
Their intrinsic ability to bend DNA has implicated these high
mobility group (HMG) proteins in an architectural role of jux-
taposing distantly located transcription factors. Recent data
suggest that TCF-1 may act as a transcriptional repressor
when associated with Groucho (Grg) proteins, and we hypoth-
esized that this particular function could explain the strong
negative and lymphocyte-specific activity of the upstream reg-
ulatory region within the ecto-59-NT promoter (38). We have
tested the activities of the wild type and TCF-1/LEF-1-mutated
969-bp ecto-59-NT promoter in Jurkat T-cells that endog-
enously express both TCF-1 and LEF-1 proteins and in HeLa
cells that lack both transcription factors. The results in Fig. 9
demonstrate that the strong negative activity of the upstream
regulatory region in Jurkat T-cells is not significantly affected
by TCF/LEF site mutagenesis. The same mutations, however,
completely eliminated gel shifts in an EMSA (data not shown),
suggesting either that the TCF-1/LEF-1 transcription factors
do not contribute or that elimination of this site alone is not
FIG. 5. A, scheme illustrating the chi-
meric dCK/ecto-59-nucleotidase promoter.
B, activity of the ecto-59-nucleotidase up-
stream regulatory region in the context of
dCK core promoter in several human cell
lines. Values represent the mean 6 S.D.
of four independent determinations done
in duplicate.
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sufficient to affect the negative activity of the upstream regu-
latory region.
DISCUSSION
The highly variable level of expression of ecto-59-NT in hu-
man and animal tissues and cells suggests tissue-specific
mechanisms controlling the expression of this enzyme. These
mechanisms are unknown; therefore, an analysis of the tran-
scriptional regulation of this gene was undertaken, and in this
study we have analyzed the tissue-specific regulatory elements
within the ecto-59-NT promoter. Sequence analysis of the 59-
flanking region of the ecto-59-NT gene reveals a number of
potential transcription factor binding sites within the 820 bp
upstream of the translation start site within the first exon (26,
39). As illustrated in Fig. 4, these sites were concentrated in
four clusters that contain a number of lymphocyte- and mac-
rophage-specific, developmentally important, as well as gen-
eral transcription factor binding elements. The occupancy of
several of these sites was confirmed by in vitro DNase I foot-
printing analysis. The number of potential regulatory elements
within the ecto-59-NT promoter suggests that there might be a
high level of complexity in the interactions between binding
factors, especially between those localized immediately 59 to
the transcription start site and those further upstream. Dele-
tional analysis of the 59-upstream fragment of the ecto-59-NT
gene confirmed that the 969-bp promoter fragment mediates
cell-specific regulation of expression. Deletion of 768 bp at the
59-end of this fragment eliminated the cell-specific expression
of the reporter gene and suggests that this 768-bp fragment
contains regulatory elements responsible for both the de-
creased promoter activity in Jurkat cells as well as the up-
regulation in fibroblasts. Further deletions within the 201-bp
fragment decreased the promoter activity in Jurkat T-cells
(data not shown); therefore, we designated this 201-bp region
as the core promoter. The dual and cell-specific function of the
768-bp upstream regulatory fragment raises important ques-
tions with regard to whether transcription factors binding to
this region confer this specificity as well as how the core pro-
moter activity relates to the upstream regulatory region.
The cell-specific regulation of the ecto-59-NT promoter may
be conferred by proteins binding to either the core promoter or
the upstream regulatory region. Mutational analysis of the
201-bp core promoter region led to several important observa-
tions. First, while single mutations at the Sp1, Sp1/AP-2, and
CRE binding sites did not alter the 201-bp core promoter ac-
tivity, mutation at the CRE had a profound effect on the pro-
moter activity when analyzed within the context of the 969-bp
fragment. Elimination of the CRE site dramatically increased
the promoter activity in Jurkat T-cells, suggesting a major role
for factors binding at this site in mediating suppression of core
promoter activity by the upstream regulatory region. In addi-
tion, mutation of the Sp1/AP-2 site caused a further decrease in
the low basal activity of the 969-bp promoter fragment in
Jurkat T-lymphocytes and a significant decrease of the pro-
moter activity in HeLa cells. In combination, these observa-
tions suggest that the regulatory function of the upstream
768-bp fragment requires the presence of specific transcription
factors within the core promoter region to either down- or
up-regulate the rate of ecto-59-NT transcription in a cell- or
tissue-specific manner. The finding that the activity of the dCK
core promoter, containing a Sp1 and E2F (half-site) transcrip-
tion factor binding site, was also inhibited by the ecto-59-NT
upstream regulatory region, suggests that the CRE site, while
essential for the negative regulation of the ecto-59-NT pro-
moter, may not be absolutely required for transcriptional re-
pression mediated by this region. Nonetheless, the abrogation
of PMA responsiveness by mutation of the CRE site strongly
supports an important role for CRE-binding proteins in regu-
lating ecto-59-NT activity. The latter conclusion is consistent
FIG. 6. The effect of mutagenesis of transcription factor bind-
ing sites within the 201- and 969-bp promoters on ecto-5*-NT
promoter activity. Transcription factor binding sites were subjected
to site-directed mutagenesis using the oligonucleotides outlined under
“Experimental Procedures.” Values represent the mean 6 S.D. of three
independent determinations done in duplicate.
FIG. 7. EMSA of the CRE binding site with Jurkat T-cell extract in the presence of antibodies against members of the CREB and
ATF family of transcription factors. A, incubations performed as described under “Experimental Procedures” (50 mM KCl). B, incubations
performed in the presence of 70 mM KCl to reduce nonspecific interactions. Cold oligonucleotide containing the mutated CRE site was added as a
competitor at a 1000-fold excess in the last lane. C, comparison of gel shift patterns of mutated (Table I) and wild-type CRE probes. D, the effect
of ATF-2 antibody on the gel shift pattern in the absence and presence of PMA treatment (20 ng/ml for 24 h).
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with reports that describe the CRE site as a PMA-responsive
element (TRE) (36, 37). The mechanism of PMA-induced ecto-
59-NT promoter activation is unknown. It is possible, however,
that as reported previously (36), PMA may induce changes in
the composition of protein complexes binding to the CRE site.
Although we have not seen a significant change in the appear-
ance of supershifts with ATF-2 antibodies in EMSA after pre-
treatment of cells with PMA (Fig. 7D), the intensity of the
lower band did not decrease as strongly as in the control,
suggesting the presence of an increased amount of other pro-
tein components in this complex. The identity of this compo-
nent and its relevance to the increased promoter activity after
treatment with PMA remain to be established.
The ecto-59-NT CRE element (TGACGTCG) differs from the
consensus CRE palindrome by one base (underlined). It has
previously been shown that single base changes in this cis-
acting DNA element may dramatically influence the binding
properties and function of this site (36, 40). We have shown
that, despite the presence of several members of the CREB/
ATF family of transcription factors in both Jurkat and HeLa
cell lines, only antibodies against ATF-1 and ATF-2 interacted
with protein complexes in EMSAs using Jurkat nuclear ex-
tracts. As a result of these interactions, two changes were
observed: (a) decreased intensities of the initial ATF-1 and
ATF-2 (lower band) complexes and (b) the appearance of the
corresponding supershifts. The existence of two distinct gel
shifts, each independently interacting with ATF-1 and ATF-2
antibodies, suggests the presence of two different species of
protein complexes at the CRE site. The absence, as evidenced
by the lack of supershifted bands of these and several other
known CREB/ATF family members as well as c-Jun and c-Fos
proteins, suggests that a different protein(s) bind to this site in
HeLa nuclear extract. These observations, in conjunction with
the higher basal promoter activity and endogenous ecto-59-NT
mRNA expression in HeLa cells, would suggest that ATF-1 and
ATF-2 transcription factors mediate low promoter activity in
lymphocytes. Whether both have the same potency in suppress-
ing the ecto-59-NT promoter activity remains to be established.
Mutation of the Sp1/AP-2 site increased the suppressive
activity of the 969-bp promoter fragment in Jurkat cells and,
interestingly, also uncovered the potential for the suppression
in HeLa cells. This finding suggests that the intrinsic ability of
the upstream regulatory region to inhibit core promoter activ-
ity may represent a more general property of this fragment and
that the tissue- and cell-specific up- and down-regulation of the
promoter activity may be more specifically mediated by factors
binding to CRE and Sp1/AP-2 sites. In that respect, and due
perhaps to the presence of NFAT, TCF/LEF, Ets, and an un-
known transcription factor in Jurkat T-cells, the overall sup-
pressive activity of the upstream regulatory region is inher-
ently more potent in Jurkat than in HeLa cells. According to
this model, the up-regulation of promoter activity in tissues
that express low to intermediate levels of ecto-59-NT would be
achieved primarily by derepression. Thus, increased ATF-1
and/or ATF-2 transcription factors binding to the CRE site
would facilitate repression of the promoter activity, whereas
increased binding to the Sp1/AP-2 site would facilitate
derepression.
The nature and specific mechanism of the negative activity of
the upstream regulatory region will be a subject for future
study. This region contains several regulatory elements that
may potentially contribute to the repressive effect. One possi-
ble candidate is transcription factor binding to the NRE-2a/2b
negative regulatory element (35, 41); however, the identity of
the specific protein(s) binding to this site has yet to be estab-
lished. Other candidates, specific for lymphocytes and of poten-
tial importance during development, are the TCF-1 and LEF-1
transcription factors. These proteins have been shown to inter-
act with the transcriptional repressor Groucho (38) and to have
an important architectural function in the context of the TCRa
enhancer (42, 43). However, since mutation of the binding site
for TCF/LEF did not produce a noticeable change in the func-
tion of this 768-bp fragment (Fig. 8), it is possible that several
interacting transcription factors might form, in a cooperative
manner, a functional higher order nucleoprotein complex in
lymphocytes. This possibility is further supported by our find-
ing that the 768-bp fragment was able to function independ-
ently in the heterologous promoter system with the 244-bp dCK
promoter. Specific cooperation among Ets, LEF-1, AML, and
CRE transcription factors has already been shown to be impor-
tant for the function of the TCRa enhancer (42–44). In this
regard, we have noted that the spatial alignment of GATA, Ets,
TCF-1/LEF-1, and CRE transcription factor binding sites in the
TCRa enhancer closely resembles their location in the ecto-
59-NT promoter (45). A similar arrangement of these transcrip-
tion factors was also found in TCRb and TCRd, CD8, and
human immunodeficiency virus enhancers (46–48). Whether
this structural alignment, with an invariably central position
of the relatively rare TCF/LEF site, carries out a specific func-
tion common to these enhancers and the ecto-59-NT promoter
remains to be established. TCF/LEF transcription factors have
been identified as nuclear targets for Wnt signaling (49–51),
and our current efforts are aimed at establishing whether the
ecto-59-NT promoter is a target for this evolutionarily con-
served and developmentally important signaling pathway.
Since only a single gene target for Wnt signaling has been
FIG. 8. The effect of PMA on the native and CRE-mutated 201-
and 969-bp promoter fragments in Jurkat T-cells. Values repre-
sent the mean 6 S.D. of three independent determinations done in
duplicate.
FIG. 9. The effect of mutation of the TCF-1/LEF-1 transcription
factor binding site on the activity of the upstream regulatory
region. Values represent the mean 6 S.D. of three independent deter-
minations done in duplicate.
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identified in mammals to date (52), the ecto-59-NT promoter
would offer an excellent model to study the mechanisms of
induction of gene expression by this pathway. Thus, further
delineation of the specific interactions involving a higher order
nucleoprotein complex of the ecto-59-NT promoter may not only
enhance our understanding of how these signaling pathways
modulate the transcription of ecto-59-NT gene but will also lead
to a better understanding of its function during development
and transformation.
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